前沿速览026期| CAR-T治B淋 前沿览新知
01
在大B细胞淋巴瘤患者人群中，基线免疫状态和T细胞克隆扩增动态与CAR-T细胞疗法的持久应答相关
Baseline Immune State and T-cell Clonal Kinetics are Associated with Durable Response to CAR-T Therapy in Large B-cell Lymphoma
第一作者：Maurer K
Blood (IF=21.0). 2024 Sep 6:blood.2024024381.
全文网址：https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2024024381/517683/Baseline-Immune-State-and-T-cell-Clonal-Kinetics?redirectedFrom=fulltext
02
桥接治疗后代谢肿瘤体积的变化可影响大B细胞淋巴瘤患者的CAR-T治疗结局
Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B cell lymphoma
第一作者：Hubbeling H
Clin Cancer Res (IF=10.0). 2024 Sep 11.
全文网址：https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-24-0830/748401/Metabolic-tumor-volume-response-after-bridging?redirectedFrom=fulltext
03
CAR-T治疗后的第二原发性恶性肿瘤：对5,517例淋巴瘤和骨髓瘤患者的系统性回顾与荟萃分析
Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients
第一作者：Tix T
Clin Cancer Res (IF=10.0). 2024 Sep 11.
全文网址：https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-24-1798/747919/Second-primary-malignancies-after-CAR-T-cell?redirectedFrom=fulltext
04
在接受CAR-T细胞治疗的大B细胞淋巴瘤患者中，基于18F-FDG PET/CT参数的分层分析：免疫抑制性肿瘤微环境是高肿瘤负荷患者的不良预后因素
18F-FDG PET/CT metrics-based stratification of large B-cell lymphoma receiving CAR-T cell therapy: immunosuppressive tumor microenvironment as a negative prognostic indicator in patients with high tumor burden
第一作者：Sheng LS
Biomark Res (IF=9.5). 2024 Sep 14;12(1):104.
全文网址：https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-024-00650-5
05
原发性中枢神经系统淋巴瘤患者接受CD19 CAR-T细胞疗法后的结局
Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy
第一作者：Mercadal S
Haematologica (IF=8.2). 2024 Sep 5.
全文网址：https://haematologica.org/article/view/haematol.2024.285613
06
代谢肿瘤体积对接受CAR-T治疗的非霍奇金淋巴瘤患者生存的影响：一项荟萃分析
Metabolic tumor volume and the survival of patients with Non-Hodgkin lymphoma treated with chimeric antigen receptor T cell therapy: a meta-analysis
第一作者：Liu L
Front Immunol (IF=5.7). 2024 Aug 29;15:1433012.
全文网址：https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1433012/full
07
CAR-T治疗血液恶性肿瘤：从基础研究、转化研究到临床实践的启示
Chimeric antigen receptor T-cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice
第一作者：Grégoire C
Br J Haematol (IF=5.1). 2024 Sep 11.
全文网址：https://onlinelibrary.wiley.com/doi/10.1111/bjh.19751
08
协变量对非霍奇金淋巴瘤患者体内Axicabtagene Ciloleucel动力学的影响
Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin's Lymphoma
第一作者：Chartier M
Clin Pharmacokinet (IF=4.6). 2024 Sep 6.
全文网址：https://link.springer.com/article/10.1007/s40262-024-01413-z
09
如何才能更好地成功识别适合CAR-T细胞疗法的患者？
How can we improve the successful identification of patients suitable for CAR-T cell therapy?
第一作者：Feng Y
Expert Rev Mol Diagn (IF=3.9). 2024 Sep 11:1-16.
全文网址：https://www.tandfonline.com/doi/full/10.1080/14737159.2024.2399152
10
弥漫大B细胞淋巴瘤患者及时接受CAR-T治疗的真实世界障碍分析
Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma
第一作者：Hu B
Transplant Cell Ther (IF=3.6). 2024 Sep 11:S2666-6367(24)00658-4.
全文网址：https://linkinghub.elsevier.com/retrieve/pii/S2666-6367(24)00658-4
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2024.10-3 valid until 2026.10
供稿与审核：临床开发与医学部